Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2005-05-03
2005-05-03
Naff, David M. (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C424S094100, C424S094500, C435S177000, C514S002600, C530S402000, C530S812000
Reexamination Certificate
active
06887842
ABSTRACT:
Bifunctional molecules and methods for their use are provided. The subject bifunctional molecules are conjugates of a drug moiety and a pharmacokinetic modulating moiety, where these two moieties are optionally joined by a linking group. The bifunctional molecules are further characterized in that they exhibit at least one modulated pharmacokinetic property upon administration to a host as compared to a free drug control. The subject bifunctional molecules find use in a variety of therapeutic applications.
REFERENCES:
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5714142 (1998-02-01), Blaney et al.
patent: 5830462 (1998-11-01), Crabtree et al.
patent: 5834266 (1998-11-01), Crabtree et al.
patent: 5840733 (1998-11-01), Krantz et al.
patent: 5843440 (1998-12-01), Pouletty et al.
patent: 5869337 (1999-02-01), Crabtree et al.
patent: 5871753 (1999-02-01), Crabtree et al.
patent: 6372712 (2002-04-01), Briesewitz et al.
patent: 6670348 (2003-12-01), Rosen et al.
patent: 20020045570 (2002-04-01), Rosen et al.
patent: WO 9101743 (1991-02-01), None
patent: WO 9418317 (1994-08-01), None
patent: WO 9502684 (1995-01-01), None
patent: WO 9505389 (1995-02-01), None
patent: WO 9510302 (1995-04-01), None
patent: WO 9606111 (1996-02-01), None
patent: WO 9612796 (1996-05-01), None
patent: WO 9613613 (1996-05-01), None
patent: WO 9725074 (1997-07-01), None
patent: WO 9729372 (1997-08-01), None
patent: WO 9800171 (1998-01-01), None
patent: WO 9811437 (1998-03-01), None
patent: WO 9846270 (1998-10-01), None
patent: WO 9847002 (1998-10-01), None
patent: WO 9847916 (1998-10-01), None
Kudak et al. “Synthesis and Evaluation of Geldanamycin-Testosterone Hybrids”Bioorg—Med. Chem.. Lett. 10(2000) 1303-1306.
Srinivasa R. Karra et al. “99m Tc-Labeling and in Vivo Studies of a Bombesin Analogue with a Novel Water—Soluble Dithiadiphosphine-Based Bifunctional Chelating Agent”Bioconjgate Chem.1999, 10, 254-260.
Snel C.A. Wilco et al. Database Biosis Online -Biosciences Information Service, Database Accession No. PREV199598364814 XP-002220714 “Disposition of the bromosulfophthalein-gluthatione conjugate in the isolated perfused rat kidney” (1995) AbstractJournal of Pharmacology and Experimental Therapeutcs, vol. 273, No. 3, 1995 (pp. 1300-1306, ISSN:0022-3565.
P.J. Hayball et al. Database Biosis Online -Biosciences Information Service, Database Accession No. 199294111953 XP002220709 “Stereoselective Interactions of Ketoprofen Glucuronides with Human Plasma Protein and Serum Albumin” AbstractBiochemical Pharmacology, vol. 44, No. 2. 1992 ppgs 291-299, ISSN:0006-2952.
I. Toth “A Novel Chemical Approach to Drug Delivery: Lipid Amino Acid Conjugates”Journal of Drug Targeting, Switzerland 1994, vol. 2, No. 3,pp. 217-239.
Al-Obeidi, et al., (1990) “Synthesis and Actions of a Melanotropin Conjugate, Ac-[Nle4, Glu(gamma-4-'-hydroxyanilide)5, D-Phe7]α -MSH4-10-NH2, on Melanocytes and Melanoma Cells In Vitro,”Journal of Pharmaceutical Sciencesvol. 79, No. (6):500-504.
Atwell, John L., et al., (1996) “Design and Expression of a Stable Bispecific scFv Dimer with Affinity for Both Glycophorin and N9 Neuraminidase,”Molecular Immunologyvol. 22, No. (17/18):1301-1312.
Belshaw, et al., (1996) “Controlling Protein Association and Subcellular Localization with a Synthetic Ligand that Induces Heterodimerization of Proteins,”Proc. Natl. Acad. Sci. U.S.A.vol. 93:4604-4607.
Bernstein, Kenneth E., et al., (1990) “A Deeply Recessed Active Site in Angiotensin-Converting Enzyme Is Indicated From the Binding Characteristics of Biotin-Spacer-Inhibitor Reagents,”Biochemical and Biophysical Communicationsvol. 167, No. (1):310-316.
Bourdouxhe-Housiaux, Catherine, et al., (1996) “Interaction on DNA-Threading Peptide-Amsacrine Conjugates With DNA and Chromatin,”Anti-Cancer Drug Designvol. 11:509-525.
Brochu, et al., (1992) “Modes of Action and Ihibitory Activities of New Siderophor-β-Lactam Conjugates that use Specific Iron Uptake Pathways for Entry into Bacteria,”Antimicrobial Agents and Chemotherapyvol. 36, No. (10):2166-2175.
Briesewitz, et al., (1999) “Affinity Modulation of Small-Molecule Ligands by Borrowing Endogenous Protein Surfaces,”P.N.A.Svol. 96, No. (5):1953-1958.
Chakraborty, TK., et al., (1995) “Design and Synthesis of a Rapamycin-Based High Affinity Binding FKBP12 Ligand,”Chemistry&Biologyvol. 2:157-161.
Crabtree, Gerald R., et al., (1996) “Three-Part Inventions: Intracellular Signalling and Induced Proximity,”Elsevier Trends Journalpp:418-422.
Heath, et al., (1986) “Liposome-Mediated Delivery of Pteridine Antifolates to cells in Vitro: Potency of Methotrexate, and its α and γ Substituents,”Biochimica et Biophysica Actavol. 862:72-80.
Ho, Steffan N., et al., (1996) “Dimeric Ligands Define a Role for Transcriptional Activation Domains In Reinitiation,”Nature, vol. 382, No. (6594):822-826.
Holt, et al., (1994) “Structure-Activity Studies of Synthetic FKBP Ligands as Peptidyl-Prolyl Isomerase Inhibitors,”Bioorganic and Medicinal Chemistry Lettersvol. 4, No. (2):315-320.
Kramer, Werner, et al., (1992) “Liver-Specific Drug Targeting by Coupling to Bile Acids,”The Journal of Biological Chemistry, vol. 267, No. (2):18598-18604.
Luengo, et al., (1994) “Synthesis and Structure-Activity Relationships of Macrocyclic FKBP Ligands,”Bioorganic and Medicinal Chemistry Lettersvol. 4, No. (2):321-324.
Lussow, et al., (1996) “Targeting of Antihapten Antibodies to Activated T Cells via an IL-2-Hapten Conjugate Prolongs Cardiac Graft Survival,”Transplantationvol. 62, No. (12):1703-1708.
Maeda, et al., (1997) “Amino Acids and Peptides XXXII: A Biofunctional Poly(Ethylene Glycol) Hybrid of Fibronectin-Related Peptides,”Biochemical and Biophysical Research Communicationsvol. 241:595-598.
Mogre, R.M., et al., (1987) “A New Carbene Based Heterbifunctional Reagent: Photochemical Crosslinking of Aldolase,”FEBS Letters, vol. 221, No. (2):408-414.
Mu, Yu., et al., (1999) “Bioconjugation of Laminin Peptide YIGSR With Poly(Styrene CO-Maleic Acid) Increases Its Antimetastaic Effect on Lung Metastasis of B16-BL6 Melanoma Cells,”Biochemical and Biophysical Research Communications, vol. 255:75-79.
Varshavsky, Alexander, (1998) “Codominant Interference, Antieffectors, and Multitarget Drugs,”Proc. Natl. Acad. Sci. USA, vol. 95:2094-2099.
Varshavsky, Alexander, (1995) “Codominance and Toxins: A Path to Drugs of Neatly Unlimited Selectivity,”Proc. Natl. Acad. Sci. USA, vol. 92:3663-3667.
Zunino, et al., (1984) “Compassion of Antitumor Effects of Daunorubicin Covalently Linked to Poly-L-Amino Acid Carries,”Eur. J. Cancer Chem. Oncol.vol. 20, No. (3):421-425.
Choi et al. (1996) “Structure of the FKBP12-Rapamycin Complex Interacting with the Binding Domain of Human FRAP.”Science, vol. 273:239-242.
Clardy (1999) “Borrowing to make ends meet.”Proc. Natl. Acad. Sci. USA, vol. 96:1826-1827.
Garboczi et al. (1996) “Structure of the complex between human T-cell receptor, viral peptide and HLA-A2.”Nature, vol. 384:134-141.
Griffith et al. (1995) “X-Ray Structure of Calcineurin Inhibited by the Immunophilin-Immunosuppressant FKBP12-FK506 Complex.”Cell, vol. 82:507-522.
Johnson et al. (1997) “Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity.”Chemistry&Biology, vol. 4:939-950.
Kissenger et al. (1995) “Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex.”Nature, vol. 378:641-644.
Klemm et al. (1997) “Rapid targeting of nuclear proteins to the cytoplasm”Current Biology, vol. 7:638-644.
Livnah et al. (1996) “Functional Mimicry of a Protein Hormone by a Peptide Agonist:
Briesewitz Roger
Crabtree Gerald R.
Wandless Thomas J.
Bozicevic Field & Francis LLP
Field Bret E.
Naff David M.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Modulating a pharmacokinetic property of a drug by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulating a pharmacokinetic property of a drug by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulating a pharmacokinetic property of a drug by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3426060